[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100428242":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":27,"centralContacts":32,"locations":40,"responsibleParty":60,"collaborators":18,"id":64,"slug":65,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":68,"acronym":18,"eligibilityCriteria":69,"healthyVolunteers":66,"sex":70,"minAge":71,"maxAge":72,"enrollmentInfo":73,"targetDuration":18,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":18,"overallStatus":43,"whyStopped":18,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"Karolinska University Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Iodine Potassium Iodide solution","EXPERIMENTAL","Participants receive Iodine Potassium Iodide solution oral drops 3 times per day for 10 Days prior to thyroidectomy in addition to standard preoperative treatment",[13],"Drug: Iodine-Potassium Iodide 5%-10% Oral and Topical Solution",{"label":15,"type":16,"description":17,"interventionNames":18},"No intervention","NO_INTERVENTION","Participants continue with standard preoperative treatment",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Iodine-Potassium Iodide 5%-10% Oral and Topical Solution","Iodine Potassium Iodide 5% oral solution, administered 3 times per day for 10 days",[9],[26],"Lugol's solution",[28],{"name":29,"affiliation":30,"role":31},"Jan Calissendorff, MD, PhD","Department of Molecular Medicine and Surgery, Karolinska Institutet","PRINCIPAL_INVESTIGATOR",[33,37],{"name":29,"role":34,"phone":35,"phoneExt":18,"email":36},"CONTACT","+46(0)8 51770000","jan.calissendorff@regionstockholm.se",{"name":38,"role":34,"phone":35,"phoneExt":18,"email":39},"Fredric Hedberg, MD","fredric.hedberg@regionstockholm.se",[41],{"facility":42,"status":43,"city":44,"state":45,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"Department of Endocrinology, Karolinska University Hospital","RECRUITING","Solna","Stockholm County","17176","Sweden","SE",{"type":50,"coordinates":51},"Point",[52,53],18.00086,59.36004,{"lat":53,"lon":52},[56,59],{"name":57,"role":34,"phone":58,"phoneExt":18,"email":36},"Jan Calissendorff, MD.PhD","0046 (0)8 51770000",{"name":38,"role":34,"phone":58,"phoneExt":18,"email":39},{"type":61,"investigatorFullName":62,"investigatorTitle":63,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"SPONSOR_INVESTIGATOR","Jan Calissendorff","MD, Senior Consultant, PhD, Associate Professor","100428242","phase-3-preoperative-lugols-solution-in-graves-disease-and-toxic-nodular-goiter-100428242",false,"NCT04856488","Preoperative Lugol's Solution in Graves' Disease and Toxic Nodular Goiter","Inclusion Criteria:\n\n* Hyperthyroidism accepted for thyroidectomy due to toxic nodular goiter with free T4 \\\u003C30 pmol\u002FL or Graves' disease\n* Signed informed consent\n\nExclusion Criteria:\n\n* Unstable coronary artery disease\n* Previous thyroid surgery\n* Congestive heart failure\n* Renal insufficiency\n* Hepatic failure\n* Current infection\n* Treatment with steroids or anticoagulants\n* Thyroid associated orbitopathy CAS \\> 2\n* Diabetes mellitus type 1\n* Active cancer\n* Severe psychiatric illness\n* Amiodarone treatment\n* Pregnancy\n* Breast feeding\n* Women of child bearing potential not using contraceptive\n* Inability to comprehend the meaning of the study\n* Iodine hypersensitivity","ALL","18 Years","75 Years",{"count":74,"type":75},182,"ESTIMATED","INTERVENTIONAL",[78],"PHASE3","The purpose of this study is to assess if preoperative treatment with Lugol's solution prior to thyroidectomy can reduce the surgical complications hypoparathyroidism and laryngeal nerve palsy",[81],"Hyperthyroidism","2026-02-06",{"date":84,"type":85},"2026-02-10","ACTUAL",{"date":87,"type":85},"2021-11-18",{"date":89,"type":75},"2028-12",{"name":62,"class":6},1]